Several medications used to treat heartburn and acid reflux are being recalled after manufacturers detected trace amounts of the same probable cancer-causing impurity that prompted earlier recalls. Reflux drug recall. Mylan pharmaceuticals has issued a voluntary nationwide recall of three lots of nizatidine capsules due to a substance that could cause cancer three lots of nizatidine capsules, usp, (including the 150mg and 300mg strengths), have been recalled due to detected trace amounts of an impurity of ndma (nitrosodimethylamine).
reflux drug recall
The recalls, posted by the food and drug administration (fda) this week, are the latest in a series that began in september 2019, when the fda alerted the public to the presence of a probable human carcinogen, n-nitrosodimethylamine (ndma), in some ranitidine medications ranitidine is the generic form of zantac. The recall comes just a few months after sanofi announced a recall of its over-the-counter heartburn drug zantac due to a possible contamination of ndma. the fda has shared preliminary results of. (rxwiki news) the us food and drug administration (fda) has released an update about the recall of a common heartburn medication. the fda has discovered that some medications used for acid reflux contain low levels of a possible cancer-causing impurity. these medications are found under the names ranitidine (active ingredient) and zantac (brand). these drugs are available over the counter and.
